FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmacy and medicine. What is presented is using a therapeutic agent containing a compound of the general formula
in a combination with at least one more therapeutic agent specified in biguanide and an α-glucosidase inhibitor for treating type 2 diabetes mellitus, diabetes complications, impaired glucose tolerance, insulin resistance or obesity, as well as the therapeutic agent based on the above combination for the same application.
EFFECT: technical effect consists in the synergetic action on an increase of the GLP-1 administration following administration of saccharose, a combination SK-0403 (a compound described by the general formula (I)) with Miglitol or metformin.
8 cl, 8 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS | 2010 |
|
RU2532330C2 |
| APPLICATION OF DPP-IV INHIBITOR FOR REDUCTION OF GLYCEMIA ACUTE EXACERBATION | 2006 |
|
RU2440143C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DIABETES MELLITUS AND OBESITY CONTAINING COMPOUND INHIBITING ACTIVITY OF DIPEPTIDYLPEPTIDASE-IV, AND OTHER ANTIDIABETIC AGENTS OR ANTIOBESITY AGENTS AS ACTIVE INGREDIENTS | 2009 |
|
RU2466727C1 |
| PHARMACEUTICAL COMBINATION CONTAINING SGLT2 INHIBITOR | 2008 |
|
RU2489151C2 |
| ACTIVE SUBSTANCE DELIVERY | 2008 |
|
RU2467741C2 |
| COMBINED THERAPY WITH GPR119 AGONISTS AND DPP-4 INHIBITORS | 2020 |
|
RU2818562C2 |
| METHOD FOR PREVENTING GLP-1 SIDE EFFECTS | 2008 |
|
RU2474415C2 |
| METHOD FOR IMPROVING SIGNAL TRANSFER IN ISLETS OF LANGERHANS IN DIABETES MELLITUS AND IN ITS PROPHYLAXIS | 2001 |
|
RU2261096C2 |
| NEW APPLICATION OF LIVER X RECEPTOR AGONISTS | 2006 |
|
RU2417078C2 |
| DIPEPTIDYL PEPTIDASE IV INHIBITING AGENT AND PHARMACEUTICAL COMPOSITION THEREOF | 2011 |
|
RU2485952C2 |
